(Q44705704)

5 December 2017

title

Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience (English)

1 reference

5 December 2017

1 reference

13

Petr Cetkovsky

1 reference

5 December 2017

Zdenek Racil

1

1 reference

5 December 2017

Jana Winterova

2

1 reference

5 December 2017

Michal Kouba

3

1 reference

5 December 2017

Pavel Zak

4

1 reference

5 December 2017

Ludmila Malaskova

5

1 reference

5 December 2017

Lucie Buresova

6

1 reference

5 December 2017

Martina Toskova

7

1 reference

5 December 2017

Martina Lengerova

8

1 reference

5 December 2017

Iva Kocmanova

9

1 reference

5 December 2017

Barbora Weinbergerova

10

1 reference

5 December 2017

Shira Timilsina

11

1 reference

5 December 2017

Monika Rolencova

12

1 reference

5 December 2017

Jiri Mayer

14

1 reference

5 December 2017

publication date

19 March 2012

1 reference

5 December 2017

1 reference

5 December 2017

volume

55

1 reference

5 December 2017

issue

6

1 reference

5 December 2017

page(s)

483-492

1 reference

Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database.

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

Voriconazole as primary antifungal prophylaxis in patients with neutropenia after hematopoietic stem cell transplantation or chemotherapy for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

Voriconazole concentrations and outcome of invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

Effect of food on the pharmacokinetics of multiple‐dose oral voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

Voriconazole : a review of its use in the management of invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

Pharmacokinetic/pharmacodynamic profile of voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

Voriconazole plasma monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

Effect of omeprazole on the steady‐state pharmacokinetics of voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

Development and validation of a high-performance liquid chromatography assay for voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

Oral versus intravenous therapy in the treatment of systemic mycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

Impact of intravenous administration of voriconazole in critically ill patients with impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

Clinician ordering practices for voriconazole therapeutic drug monitoring: experiences of a referral laboratory

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

Voriconazole therapeutic drug monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

Factors associated with mortality in transplant patients with invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

Human tissue distribution of voriconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2012.02186.X

10.1111/J.1439-0507.2012.02186.X

21 January 2018

Identifiers

DOI

1 reference

5 December 2017

1 reference